companiesCompany
Fennec Pharmaceuticals
aka Adherex Technologies, Fennec Pharmaceuticals Inc., NASDAQ:FENC
Fennec Pharmaceuticals is the North Carolina company behind Pedmark, the sodium thiosulfate infusion given after cisplatin to protect children's hearing from the chemotherapy.
Overview
Fennec Pharmaceuticals, formerly Adherex Technologies, developed Pedmark (sodium thiosulfate) as an otoprotectant. Given six hours after each cisplatin dose, it neutralises the platinum that damages inner-ear hair cells; the SIOPEL 6 and ACCL0431 trials showed roughly halved rates of hearing loss in children with localised solid tumours. The FDA approved Pedmark in September 2022 for patients aged one month and older, and the European Union approved it as Pedmarqsi in 2023.
Headquarters
Research Triangle Park, North Carolina, US
Scorecard
All companies#190of 1181 companies, score 24
- approved products +6
- modalities +2
- regions +3
- registry trials +13
1 approved, 0 in phase 3, 0 earlier, 0 targets, 43 registry studies. Formula on the scorecards page.
Type
pharma · NASDAQ:FENC
Stage
Public
Website